Herbalife stock tumbles as CEO Gratziani to step down in 2026

This is more of a governance/credibility event than an immediate P&L event. Because the transition is long-dated and the CFO is stepping in, the near-term earnings bridge likely does not change much; the real pressure is on the multiple, not the current-year EBITDA path. For a business that trades heavily on distributor confidence, even a planned handoff can matter if the market reads it as the end of the turnaround story rather than a continuation.

Second-order risk is that leadership changes can show up first in channel behavior, not reported numbers. If distributors sense strategic drift or reduced urgency, recruitment and retention can soften before net sales do, which would compress margins later through higher promo/comp expenses. That makes the next 1-2 reported quarters the key checkpoint: if active distributor trends or currency-adjusted sales momentum slow, the selloff can extend well beyond the initial headline reaction.

The spillover read-through is negative for other brittle direct-selling names with opaque unit economics, especially NUS, USNA, and MED, where the market already assigns a governance discount. But the contrarian point is that the board is using a structured, delayed transition after a turnaround, which argues for less disruption than a sudden departure. If guidance holds and the next two prints confirm growth, this may prove to be an overdone de-rating rather than the start of a new fundamental leg down.